Literature DB >> 9057590

p53: functions, mutations and sarcomas.

J Hung1, R Anderson.   

Abstract

The p53 gene is the most commonly altered gene in a multitude of human cancers. The alterations can be acquired somatically or transmitted through the germ-line. Bone and soft tissue sarcomas are frequently found to have acquired abnormalities in the p53 and mdm-2 genes. In soft tissue sarcoma, the amplification of the mdm-2 gene and the binding of its oncogene product to wild-type p53 protein functionally inactivates normal p53-regulated growth. Inherited mutations of the p53 gene are associated with the rare Li-Fraumeni familial cancer syndrome. Various tumor types arise in these families, with sarcomas of the bone and soft tissues and carcinoma of the breast being the most frequently observed. Transgenic mice with highly expressed mutated p53 have a higher incidence of tumors, including predominantly osteosarcomas and soft tissue sarcomas. In close similarity with the Li-Fraumeni syndrome, homozygously p53-null mice (transgenic mice carrying two non-functional p53 allele) are developmentally normal however they are susceptible to spontaneous tumor formation. This article reviews briefly the structure, function, and dysfunction of the p53 tumor-suppressor gene with particular focus on its role in the development of bone and soft tissue sarcoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9057590     DOI: 10.1080/17453674.1997.11744705

Source DB:  PubMed          Journal:  Acta Orthop Scand Suppl        ISSN: 0300-8827


  9 in total

1.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

2.  Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas.

Authors:  Mateusz Opyrchal; Ileana Aderca; Evanthia Galanis
Journal:  Methods Mol Biol       Date:  2009

Review 3.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

4.  P53 Overexpression as an Indicator of Overall Survival and Response to Treatment in Osteosarcomas.

Authors:  Zsuzsa Pápai; Christina N Féja; Eid N Hanna; Mariann Sztán; Edit Oláh; Miklós Szendrôi
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

Review 5.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

Review 6.  Genetic unraveling of colorectal cancer.

Authors:  Sabha Rasool; Vamiq Rasool; Tahira Naqvi; Bashir A Ganai; Bhahwal Ali Shah
Journal:  Tumour Biol       Date:  2014-02-27

7.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02

8.  Defective osteogenic differentiation in the development of osteosarcoma.

Authors:  Eric R Wagner; Gaurav Luther; Gaohui Zhu; Qing Luo; Qiong Shi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Yanhong Gao; Ke Yang; Linyuan Wang; Chad Teven; Xiaoji Luo; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Yang Bi; Bai-Cheng He; Ni Tang; Jinyong Luo; Liang Chen; Guowei Zuo; Richard Rames; Rex C Haydon; Hue H Luu; Tong-Chuan He
Journal:  Sarcoma       Date:  2011-02-22

9.  Guidelines for histopathological specimen examination and diagnostic reporting of primary bone tumours.

Authors:  D Charles Mangham; Nicholas A Athanasou
Journal:  Clin Sarcoma Res       Date:  2011-07-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.